VICH Topic GL26 BIOLOGICALS: TESTING OF RESIDUAL MOISTURE

Similar documents
VICH Topic GL32 STUDIES TO EVALUATE THE SAFETY OF RESIDUES OF VETERINARY DRUGS IN HUMAN FOOD: DEVELOPMENTAL TOXICITY TESTING

VICH Topic GL29. at Step 7 GUIDELINE ON PHARMACOVIGILANCE OF VETERINARY MEDICINAL PRODUCTS. MANAGEMENT OF PERIODIC SUMMARY UPDATE REPORTS (PSUs)

VICH Topic GL2 (Validation: Methodology) GUIDELINE ON VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)

VICH Topic GL10. Step 7 (after revision at step 9) GUIDELINE ON IMPURITIES IN NEW VETERINARY DRUG SUBSTANCES

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)

VICH Topic GL3. Step 7 (after revision at step 9) GUIDELINE ON STABILITY: STABILITY TESTING OF NEW VETERINARY DRUG SUBSTANCES AND MEDICINAL PRODUCTS

European Medicines Agency Inspections

Reflection paper on risk mitigation measures related to the environmental risk assessment of veterinary medicinal products

VICH Topic GL44. at Step 4 GUIDELINE ON TARGET ANIMAL SAFETY FOR VETERINARY LIVE AND INACTIVATED VACCINES

Reflection paper on risk mitigation measures related to the environmental risk assessment of veterinary medicinal products

EDICT ± OF GOVERNMENT

Guideline on requirements for the production and control of immunological veterinary medicinal products

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) GUIDELINE ON REQUIREMENTS FOR VACCINE ANTIGEN MASTER FILE (VAMF) CERTIFICATION

VICH Topic GL49. at step 4 GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS USED IN RESIDUE DEPLETION STUDIES

Agreed by the ERAWP April Adopted by the CVMP for release for consultation 4 June 2015

European Medicines Agency Evaluation of Medicines for Human Use

VICH GL51: Quality: statistical evaluation of stability data

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE WITH PHARMACOVIGILANCE REGULATORY OBLIGATIONS

Guidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs

London, 11 October 2006 Doc. Ref. EMEA/CHMP/BWP/271475/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)

An analysis of quality product defects in the centralised procedure

Overview of comments received on 'Draft Guideline on the chemistry of active substances (veterinary) (EMA/CVMP/QWP/49477/2017)

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE: MANUFACTURE OF THE FINISHED DOSAGE FORM

SUBMISSION OF COMMENTS ON GUIDELINE ON VIRUS SAFETY EVALUATION OF BIOTECHNOLOGICAL INVESTIGATIONAL MEDICINAL PRODUCTS - EMEA/CHMP/BWP/398498/2005

Medicinal product no longer authorised

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

Guideline on setting specifications for related impurities in antibiotics

Adoption by CVMP for release for consultation 11 November End of consultation (deadline for comments) 31 May 2010

PROCEDURE FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS REQUESTED BY THE CVMP. Ad Hoc PhV Inspectors Working Group

Draft for comments only Not to be cited as East African Standard

Guideline on data requirements for immunological veterinary medicinal products intended for minor use or minor species (MUMS)/limited market

Performance indicators for the EMEA in 2003

2 Chemicals, Apparatus and Unit Operations of Analytical Chemistry

Reflection paper on the use of heat treatment to inactivate endogenous retroviruses in live immunological veterinary medicinal products

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Title: Processing pharmacovigilance data in renewal procedures for centrally authorised medicinal products for veterinary use

Joint CVMP/CHMP Working group on the Application of the 3Rs in Regulatory Testing of Medical Products

VOLUME 6C. Guidance on the Assessment of environmental risks of veterinary medicinal products. June 2009

ICH Topic E15 Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories.

Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON SUMMARY OF REQUIREMENTS FOR ACTIVE SUBSTANCES IN PART II OF THE DOSSIER

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

VICH GL42: Pharmacovigilance: data elements for submission of adverse event reports (AERs)

ISO 6496 INTERNATIONAL STANDARD. Animal feeding stuffs Determination of moisture and other volatile matter content

Environmental Express. Joe Boyd. Solids and BOD Analyses: Pitfalls and Troubleshooting

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Guidelines on good pharmacovigilance practices (GVP)

Dry matter content and fibre content

In ensuring the safety of veterinary vaccines demonstration of freedom from EA is one of high importance.

Mandate and objectives for the EMA Working Party on Quality Review of Documents (QRD)

Procedural advice on publication of information on negative opinions and refusals of marketing authorisation applications for human medicinal products

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) POSITION PAPER ON NON-CLINICAL SAFETY STUDIES TO SUPPORT CLINICAL TRIALS WITH A SINGLE MICRODOSE

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers

Dryer Drum Plant Certification Report

Reflection paper on the dissolution specification for generic solid oral immediate release products with systemic action

Overview of the Agency s role, activities and priorities for An agency of the European Union

European Medicines Agency Inspections

DETERMINING MOISTURE CONTENT OF BITUMINOUS MIXTURES

COMMITTEE FOR THE MEDICINAL PRODUCT FOR HUMAN USE (CHMP)

DRAFT UGANDA STANDARD

SOUTH AFRICAN NATIONAL STANDARD

Agreed by VICH Steering Committee January Adoption by CVMP 12 February Date for coming into effect January 2016

ICH Topic Q 3 B Impurities in New Medicinal Products

Partly O-(2-hydroxyethylated) cellulose. It may contain suitable ph-stabilisers such as phosphates.

Guidelines on good pharmacovigilance practices (GVP)

Comments from: Leem (Les entreprises du Médicament)

Tooling gelcoat MGS F 300

Development of standard laboratory based test to measure compost stability Annex A

Guideline on Similar Biological Medicinal Products

BULK SPECIFIC GRAVITY OF COMPACTED HOT MIX ASPHALT (HMA) USING SATURATED SURFACE-DRY SPECIMENS FOP FOR AASHTO T 166 (11)

DRAFT EAST AFRICAN STANDARD

LAP-001. Procedure Title: Author: Tina Ehrman. Date: 10/28/94 ISSUE DATE: 11/1/94 SUPERSEDES: 8/17/92. Ethanol Project

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE 1 : DNA VACCINES NON-AMPLIFIABLE IN EUKARYOTIC CELLS FOR VETERINARY USE

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS

Effect of Heat and Air on Asphalt Materials (Thin-Film Oven Test)

Draft agreed by VICH Steering Committee January Adopted by CVMP for release for consultation 16 February 2017

Standard Specification for Chemical Admixtures for Concrete 1

Standard Specification for Chemical Admixtures for Concrete 1

Single market, implementation and legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations.

Product Permission Document (PPD) of Botulinum Toxin Type A for Injection Ph.Eur Purified Neurotoxin Complex

12. Environmental-, soil-, water-, food analysis Sample preparation for standard methods

EDICT ± OF GOVERNMENT

VICH Topic GL36 STUDIES TO EVALUATE THE SAFETY OF RESIDUES OF VETERINARY DRUGS IN HUMAN FOOD: GENERAL APPROACH TO ESTABLISH A MICROBIOLOGICAL ADI

ENGI Environmental Laboratory. Lab #2. Solids Determination. Faculty of Engineering & Applied Science

Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the Paediatric Committee (PDCO)

European Medicines Agency

6. PREPARATION OF LABORATORY-MIXED, LABORATORY-COMPACTED SPECIMENS

National Veterinary Assay Laboratory Ministry of Agriculture, Forestry and Fisheries

Pharmacovigilance. An agency of the European Union

SECTION A. American Society for Testing and Materials (ASTM):

Transcription:

The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections CVMP/VICH/096/01-Final London, 30 April 2002 VICH Topic GL26 Step 7 BIOLOGICALS: TESTING OF RESIDUAL MOISTURE ADOPTION BY CVMP FOR RELEASE FOR CONSULTATION February 2001 TRANSMISSION TO INTERESTED PARTIES February 2001 COMMENTS REQUESTED BEFORE August 2001 FINAL ADOPTION BY CVMP May 2002 DATE OF COMING INTO EFFECT May 2003 Public 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 47 E-mail: mail@emea.eu.int http://www.emea.eu.int Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged

VICH GL26 (BIOLOGICALS: MOISTURE) April 2002 For implementation at Step 7 - Final TESTING OF RESIDUAL MOISTURE Recommended for Implementation on April 2002 by the VICH Steering Committee THIS GUIDELINE HAS BEEN DEVELOPED BY THE APPROPRIATE VICH EXPERT WORKING GROUP AND WAS SUBJECT TO CONSULTATION BY THE PARTIES, IN ACCORDANCE WITH THE VICH PROCESS. AT STEP 7 OF THE PROCESS THE FINAL DRAFT IS RECOMMENDED FOR ADOPTION TO THE REGULATORY BODIES OF THE EUROPEAN UNION, JAPAN AND USA. Public EMEA/CVMP/VICH/096/01/Final 30 April 2002 Page 2/5

TABLE OF CONTENTS INTRODUCTION 1. Objective of Guideline 2. Scope of the Guideline 3. Background 4. General Principal PROPOSED GUIDELINE 1. Definition of samples to be used for testing 2. General Test procedure Public EMEA/CVMP/VICH/096/01/Final 30 April 2002 Page 3/5

INTRODUCTION 1) Objective of Guideline Freeze-dried veterinary vaccines always contain some water, commonly known as residual moisture (RM). It is important to determine the level of RM in final products, since a satisfactory test gives assurance of an adequate shelf life and that the manufacturer s freeze-dry cycle was properly controlled. The RM test should confirm that moisture level is consistently within the manufacturer s specification. This document provides a guideline on the general requirements for residual moisture testing. The guideline leaves the flexibility for other test methods based on the specific scientific situations or characteristics of the target material. These variations must be stated in the manufacturer s production method and include equivalence data. It is recognized that the limits for the alternative equivalent assay may be different from the gravimetric assay. 2) Scope of Guideline This guideline applies to final product testing for all freeze-dried new veterinary vaccines. 3) Background Three common methods are generally recognized for use in determining residual moisture, these are: Titrimetric method, (Karl Fischer) Azeotropic method Gravimetric method. Neither EU or USDA specify a test for residual moisture. The USA Code of Federal Regulations (9CFR 113.29) states a suitable method used to determine the moisture content shall be described in an outline of production approved for filing by APHIS. The EU Directives/Guidelines state that each batch <of product> is tested for residual humidity and Where applicable, the freeze-drying process is checked by a determination of water and shown to be within the limits set for the product. Japanese Standard Requirements specify the loss on drying method. 4) General Principle Residual moisture is determined by the gravimetric method as follows: Residual moisture is driven from the test product by heating under vacuum. The residual moisture content (as per cent) of the test product is calculated based the product weight loss during the drying cycle. Public EMEA/CVMP/VICH/096/01/Final 30 April 2002 Page 4/5

Residual Moisture Assay 1. Materials and equipment 1.1 Cylindrical weighing bottles--individually numbered with airtight glass stoppers. 1.2 Vacuum oven--equipped with validated thermometer and thermostat. A suitableair-drying device must be attached to the inlet valve. 1.3 Balance--capable of readability to 0.1 mg (rated precision ± 0.1 mg). 1.4 Desiccator--with phosphorus pentoxide, silica gel or equivalent 1.5 Sample--desiccated veterinary vaccine in original sealed vial. 2. Preparation for the test 2.1 Preparation for the test Environment Conduct all operations in an environment with a relative humidity less than 45%. 2.2 Preparation for the test Weighing bottles Label the weighing bottle for sample(s). Thoroughly clean weighing bottles. Place stopper at an angle on top of bottle and dry for a minimum of 30 minutes at 60 ± 3 C under vacuum (<2.5 kpa). While hot, immediately transfer bottles and stoppers into a desiccator. Allow to cool to room temperature, close stopper, weigh and record the weights as A. Return bottles to desiccator. 2.3 Preparation of the sample. Retain sample, in original airtight containers at room temperature until use. Do not break the seal until ready to proceed. 3. Performance of the test 3.1 Procedure 3.1.1 Break sample container seal. Using a spatula, break up desiccated product and rapidly transfer (minimum of 100 mg or the amount required for a precise determination at the lower limit, use more than one vial for single dose products if needed) to a previously weighed bottle. Close stopper and immediately weigh. Record the weight as B. 3.1.2 Place the bottle with the stopper at an angle in the vacuum oven. Set vacuum to <2.5 kpa and the temperature to 60 ± 3 C. 3.1.3 After a minimum of 3 hrs, turn off the vacuum pump and bleed dry air into the oven until the pressure inside of the oven is equalized with the atmosphere. 3.1.4 While the bottle is still warm, stopper bottle and transfer to desiccator, and allow to cool to room temperature (for a minimum of two hours or a time validated to yield a constant weight). Weigh, and record the weight as C. 4. Calculations and Results Calculate the residual moisture (%) as ((B - C) / (B - A)) X (100) A is tare weight of bottle. B minus A is weight of sample before assay. B minus C is weight equivalent to residual moisture of sample. Public EMEA/CVMP/VICH/096/01/Final 30 April 2002 Page 5/5